Neuronetics Inc
STIM1.560USD
+0.140+9.86%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
106.77MCap. mercado
PérdidaP/E TTM
Más Datos de Neuronetics Inc Compañía
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Información de Neuronetics Inc
Símbolo de cotizaciónSTIM
Nombre de la empresaNeuronetics Inc
Fecha de salida a bolsaJun 28, 2018
Director ejecutivoMr. Keith J. Sullivan
Número de empleados716
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección3222 Phoenixville Pike
CiudadMALVERN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19355
Teléfono18776007555
Sitio Webhttps://neurostar.com/neuronetics/
Símbolo de cotizaciónSTIM
Fecha de salida a bolsaJun 28, 2018
Director ejecutivoMr. Keith J. Sullivan
Ejecutivos de Neuronetics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+6410.00%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+10531.00%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
570.21K
+170212.00%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+7554.00%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+7326.00%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+30000.00%
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+6410.00%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+10531.00%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
570.21K
+170212.00%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+7554.00%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+7326.00%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+30000.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Clinic revenue
21.81M
58.47%
Treatment sessions
10.76M
28.84%
NeuroStar Advanced Therapy System
3.96M
10.61%
Other
776.00K
2.08%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
36.25M
97.19%
International
1.05M
2.81%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Clinic revenue
21.81M
58.47%
Treatment sessions
10.76M
28.84%
NeuroStar Advanced Therapy System
3.96M
10.61%
Other
776.00K
2.08%
Estadísticas de accionistas
Actualizado: vie., 2 de ene
Actualizado: vie., 2 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
9.97%
UBS Financial Services, Inc.
3.81%
The Vanguard Group, Inc.
3.77%
BlackRock Institutional Trust Company, N.A.
3.10%
Otro
49.08%
Accionistas
Accionistas
Proporción
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
9.97%
UBS Financial Services, Inc.
3.81%
The Vanguard Group, Inc.
3.77%
BlackRock Institutional Trust Company, N.A.
3.10%
Otro
49.08%
Tipos de accionistas
Accionistas
Proporción
Private Equity
30.28%
Individual Investor
19.61%
Investment Advisor
13.93%
Hedge Fund
9.59%
Investment Advisor/Hedge Fund
6.14%
Research Firm
1.71%
Bank and Trust
0.10%
Pension Fund
0.05%
Venture Capital
0.04%
Otro
18.55%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
216
42.40M
61.91%
-15.44M
2025Q3
198
39.45M
57.60%
-13.65M
2025Q2
187
47.56M
71.93%
-4.03M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Madryn Asset Management, LP
20.74M
30.28%
-3.50M
-14.44%
Aug 08, 2025
Chernett (Jorey)
4.40M
6.43%
+4.40M
--
Nov 17, 2025
UBS Financial Services, Inc.
2.16M
3.16%
+1.85M
+580.70%
Sep 30, 2025
The Vanguard Group, Inc.
2.83M
4.14%
+89.50K
+3.26%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
3.1%
+75.30K
+3.68%
Sep 30, 2025
Cucuz (Sasha)
2.03M
2.97%
+6.41K
+0.32%
Oct 20, 2025
Balyasny Asset Management LP
1.82M
2.66%
+312.55K
+20.71%
Sep 30, 2025
Sullivan (Keith J)
1.61M
2.35%
--
--
Mar 24, 2025
Wexford Capital LP
1.18M
1.72%
+534.15K
+83.06%
Sep 30, 2025
Masters Capital Management, L.L.C.
1.00M
1.46%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
AdvisorShares Psychedelics ETF
3.31%
Invesco NASDAQ Future Gen 200 ETF
0.43%
iShares Neuroscience and Healthcare ETF
0.1%
Vanguard US Momentum Factor ETF
0.04%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Ver más
AdvisorShares Psychedelics ETF
Proporción3.31%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.43%
iShares Neuroscience and Healthcare ETF
Proporción0.1%
Vanguard US Momentum Factor ETF
Proporción0.04%
iShares Micro-Cap ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
